PolyPid (PYPD) vs SkinHealth Systems (SKIN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
PolyPid (PYPD) has outperformed SkinHealth Systems (SKIN) over the past year, gaining 42.9% versus a loss of 66.5%. Over five years, SKIN leads with a -97.8% price change compared with -97.8% for PYPD. PolyPid is the larger company by market cap ($99.5 million vs $74.0 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PYPD | SKIN |
|---|---|---|
| Share price | $4.90 | $0.5689 |
| Market cap | $99.53M | $74.04M |
| 1-day change | -1.01% | -3.56% |
| YTD return | +12.90% | -59.07% |
| 1-year return | +42.86% | -66.54% |
| 5-year return | -97.83% | -97.78% |
| Forward P/E | — | 2.99 |
| EPS (TTM) | $-1.44 | $-0.23 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.73 | $1.74 |
| 52-week low | $3.06 | $0.55 |
| Distance from 52-week high | -14.49% | -67.30% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +139.80% | +74.02% |
| Average volume | 176.73K | 489.80K |
| Shares outstanding | 20.31M | 130.14M |
| Employees | 69 | 613 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PYPD has outperformed SKIN by 109.4 percentage points over the past year.
About PolyPid
PYPD stock →PolyPid Ltd., a biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.
Health Care · Medical/Dental Instruments · 69 employees
About SkinHealth Systems
SKIN stock →SkinHealth Systems Inc., a global medical aesthetics company delivering an integrated ecosystem of clinically proven solutions in the Americas, the Asia-Pacific, Europe, the Middle East, Africa, Canada, and Latin America. The company's flagship product is HydraFacial, which enhances the skin to cleanse, extract, and hydrate the skin with proprietary solutions and serums.
Health Care · Medical/Dental Instruments · 613 employees
PYPD vs SKIN FAQ
Which is bigger, PolyPid or SkinHealth Systems?
PolyPid (PYPD) is larger, with a market capitalization of $99.53M compared with $74.04M for SkinHealth Systems (SKIN).
Which stock has performed better over the past year, PYPD or SKIN?
PYPD returned +42.86% over the past 12 months, compared with -66.54% for SKIN (price return, excluding dividends). Past performance does not predict future results.
Are PolyPid and SkinHealth Systems in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.